Şunu aradınız:: adenocarcinoma (İngilizce - Danca)

adenocarcinoma
adenocarcinom

non-adenocarcinoma
ikke-adenocarcinoma

gastric adenocarcinoma
gastrisk adenocarcinom

(n = 1725) adenocarcinoma
(n = 1725) adenocarcinom

clear cell adenocarcinoma
carcinoma claracella

non-adenocarcinoma female
ikke-adenocarcinoma kvinder

renal adenoma or adenocarcinoma
hypernephrom

adenocarcinoma in situ of the cervix
livmoderhals-adenokarcinom

dose adjustments during treatment of pancreatic adenocarcinoma
dosisjustering i løbet af behandlingen af adenokarcinom i pancreas

the vast majority of patients had adenocarcinoma (92.1%).
størstedelen af patienterne havde adenocarcinom (92,1 %).

efficacy of docetaxel in the treatment of patients with gastric adenocarcinoma
effekten af docetaxel ved behandling af patienter med gastrisk adenocarcinom

table 1: dose level reductions for patients with pancreatic adenocarcinoma
tabel 1: reduktion i dosisniveau for patienter med adenokarcinom i pancreas

gastric cancer and gastro-oesophageal junction (gej) adenocarcinoma
gastrisk cancer og adenokarcinom i den gastroøsofagale overgang (gej)

(5) progression of pre-existing pancreatic adenocarcinoma with kras mutation.
(5) progression af præeksisterende pankreatisk adenokarcinom med kras-mutation

chronic myelomonocytic leukaemia(2)(4), pancreatic adenocarcinoma(5)
kronisk myelomonocytær leukæmi(2)(4), pankreatisk adenokarcinom5

histology <0.0001 4.4 times higher in adenocarcinoma than in non-adenocarcinoma
histologi <0,0001 4,4 gange højere hos dem med adenocarcinom end hos dem, der ikke har adenocarcinom

29 adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease.
patienterne havde ikke tidligere modtaget kemoterapi for metastatisk sygdom.

limited information is available in alk-positive nsclc patients with non-adenocarcinoma histology.
der er begrænset information tilgængelig om alk-positive nsclc-patienter med ikke-adenocarcinom-histologi.

progression of a type of pre-existing cancers with ras mutations (chronic myelomonocytic leukaemia, pancreatic adenocarcinoma)
forværring af allerede eksisterende typer kræft med ras-mutationer (kronisk myelomonocytær leukæmi, adenokarcinom i bugspytkirtlen).

diarrhoea occurred in 43.4 % (≥ grade 3: 6.3 %) of adenocarcinoma patients in the nintedanib arm.
diarré forekom hos 43,4 % (≥ grad 3: 6,3 %) af adenokarcinom patienterne i nintedanib gruppen.